Elo Mutual Pension Insurance Co Trims Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Elo Mutual Pension Insurance Co decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,877 shares of the medical equipment provider’s stock after selling 292 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Intuitive Surgical were worth $14,180,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Ridgewood Investments LLC bought a new stake in Intuitive Surgical during the 2nd quarter valued at about $26,000. Creekmur Asset Management LLC increased its holdings in Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares during the period. LGT Financial Advisors LLC grew its position in shares of Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares in the last quarter. Delos Wealth Advisors LLC lifted its stake in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares during the period. Finally, LRI Investments LLC bought a new position in Intuitive Surgical during the 1st quarter worth about $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $483.32 on Wednesday. The stock has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18. The company has a 50 day moving average price of $465.50 and a 200 day moving average price of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ISRG shares. Evercore ISI cut their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price target for the company. Morgan Stanley boosted their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Barclays increased their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $446.45.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the transaction, the general counsel now owns 1,595 shares in the company, valued at $757,625. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.